Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 19-11-2024, 13:00

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa 15-10-2023, 20:03

Pain Management Devices Market Estimated to Reach $3.3 1-02-2023, 20:23